Merck & Co. Inc. hopes to boost sales of its combination antibiotic Zerbaxa by adding hospital-acquired bacterial pneumonia to its labeling, but even with Phase III data in hand showing non-inferiority to meropenem in that setting, the value proposition for this indication is uncertain.
On Sept. 11, the pharma unveiled top-line data from the Phase III ASPECT-NP study showing that Zerbaxa (ceftolozane/tazobactam) demonstrated non-inferiority...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)